AbbVie EVP exercises options, sells 22,381 shares

AbbVie Inc. executive Perry C. Siatis, EVP, General Counsel and Secretary, reported multiple stock option exercises and a related share sale.

Rhea-AI Filing Summary

AbbVie Inc. executive Perry C. Siatis, EVP, General Counsel and Secretary, reported multiple stock option exercises and a related share sale. On February 25, 2026, he exercised options covering 7,314, 7,775 and 7,292 AbbVie shares at exercise prices of $149.62, $175.28 and $192.86 per share under the AbbVie Amended and Restated 2013 Incentive Stock Program. These exercises delivered an equal number of AbbVie common shares. On the same date, he sold 22,381 AbbVie shares in an open-market transaction at $230.00 per share. After these transactions, Siatis directly held 38,137 AbbVie common shares.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 7 txns

Insider Siatis Perry C

Role EVP, GC AND SECRETARY

Sold 22,381 shs ($5.15M)

Approx. gross sale proceeds $5.15M

Approx. exercise cost $3.86M

Type	Security	Shares	Price	Value
Exercise	Option (Right to buy)	7,314	$149.62	$1.09M
Exercise	Option (Right to buy)	7,775	$175.28	$1.36M
Exercise	Option (Right to buy)	7,292	$192.86	$1.41M
Exercise	Common Stock, $0.01 par value	7,314	$149.62	$1.09M
Exercise	Common Stock, $0.01 par value	7,775	$175.28	$1.36M
Exercise	Common Stock, $0.01 par value	7,292	$192.86	$1.41M
Sale	Common Stock, $0.01 par value	22,381	$230.00	$5.15M

Holdings After Transaction: Option (Right to buy) — 22,357 contracts (Direct); Common Stock, $0.01 par value — 38,137 shares (Direct)

Footnotes (3)

1. F1. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026.
2. F2. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027.
3. F3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028.

FAQ

What did AbbVie (ABBV) executive Perry Siatis report in this Form 4?

Perry Siatis reported exercising employee stock options and selling AbbVie shares. He converted options into 22,381 common shares, then sold 22,381 shares in the open market, and reported his updated direct ownership position in AbbVie stock.

How many AbbVie (ABBV) shares did Perry Siatis sell and at what price?

Perry Siatis sold 22,381 AbbVie common shares in an open-market transaction at $230.00 per share. This transaction followed the exercise of employee stock options that delivered the same number of AbbVie shares into his direct ownership.

What stock options did Perry Siatis exercise in AbbVie (ABBV)?

He exercised three tranches of employee stock options covering 7,314, 7,775 and 7,292 AbbVie shares. The exercise prices were $149.62, $175.28 and $192.86 per share, respectively, under AbbVie’s Amended and Restated 2013 Incentive Stock Program.

What is Perry Siatis’s AbbVie (ABBV) share ownership after these transactions?

After exercising options and selling shares, Perry Siatis directly holds 38,137 AbbVie common shares. This updated ownership figure reflects the net effect of the option exercises and the subsequent open-market sale reported in the Form 4 filing.

Were the AbbVie (ABBV) options exercised by Perry Siatis part of an incentive plan?

Yes. The options exercised were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program. Footnotes state the grants were employee stock options that became exercisable in specified annual increments on various February vesting dates.

Did Perry Siatis buy AbbVie (ABBV) shares on the open market in this Form 4?

No. The filing shows option exercises that converted derivative awards into AbbVie common shares, followed by an open-market sale. There is no indication of an open-market purchase of additional AbbVie shares in this particular Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/27/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siatis Perry C

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC AND SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/25/2026		M		7,314	A	$149.62	45,451	D
Common Stock, $0.01 par value	02/25/2026		M		7,775	A	$175.28	53,226	D
Common Stock, $0.01 par value	02/25/2026		M		7,292	A	$192.86	60,518	D
Common Stock, $0.01 par value	02/25/2026		S		22,381	D	$230	38,137	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$149.62	02/25/2026		M			7,314	(1)	02/15/2033	Common Stock	7,314	$149.62	0	D
Option (Right to buy)	$175.28	02/25/2026		M			7,775	(2)	02/14/2034	Common Stock	7,775	$175.28	7,774	D
Option (Right to buy)	$192.86	02/25/2026		M			7,292	(3)	02/12/2035	Common Stock	7,292	$192.86	14,583	D

Explanation of Responses:

1. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,315 on February 16, 2024, 7,315 on February 16, 2025, and 7,314 on February 16, 2026.

2. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 7,775 on February 15, 2025 and 7,775 on February 15, 2026, and becomes exercisable as to 7,774 shares on February 15, 2027.

3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,292 shares on February 13, 2026 and becomes exercisable in annual increments of 7,292 on February 13, 2027, and 7,291 on February 13, 2028.

	/s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.